Adverse Events of BRAF and MEK Inhibitors

MICHAEL A. POSTOW, MD
Wednesday, February 27, 2019


Each type of cancer treatment has its own adverse event (AE) profile, and BRAF and MEK inhibitors are no different, explained Michael A. Postow, MD, medical oncologist at Memorial Sloan Kettering Cancer Center.

In advanced melanoma, AEs may differ depending on the drug combination that a patient is prescribed. Those who are on dabrafenib (Tafinlar) and trametinib (Mekinist) are more likely to experience fever and chills. And if they do, it is important that providers hold treatment until these symptoms go away.

Patients prescribed vemurafenib (Zelboraf) plus cobimetinib (Cotellic) may be more likely to experience skin-related AEs, and need to be careful when it comes to sun exposure.

Finally, patients who take encorafenib (Braftovi) and binimetinib (Mektovi) may be more susceptible to arthralgia.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.